These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1615218)

  • 1. Combination therapy with flutamide and castration (orchiectomy or LH-RH agonist) in untreated patients with advanced prostate cancer.
    Dupont A; Labrie F; Cusan L; Gomez JL; Tremblay M; Lacourcière Y; Emond J; Monfette G
    Recent Results Cancer Res; 1992; 124():43-54. PubMed ID: 1615218
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
    J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
    J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.
    Labrie F; Dupont A; Cusan L; Manhès G; Bergeron N; Lacourcière Y; Pineault S; Bélanger A; Monfette G; Emond J
    J Steroid Biochem; 1989 Oct; 33(4B):817-21. PubMed ID: 2689788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
    J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.
    Ferguson J; Zincke H; Ellison E; Bergstrahl E; Bostwick DG
    Urology; 1994 Jul; 44(1):91-5. PubMed ID: 8042266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete androgen blockade as primary treatment for advanced metastatic cancer of the prostate.
    Larsen JF; Walter S; Krarup T
    Int Urol Nephrol; 1990; 22(3):249-55. PubMed ID: 2210981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
    Labrie F; Dupont A; Cusan L; Manhès G; Bergeron N; Lacourcière Y; Pineault S; Bélanger A; Monfette G; Emond J
    Prog Clin Biol Res; 1989; 303():161-7. PubMed ID: 2674982
    [No Abstract]   [Full Text] [Related]  

  • 11. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment with flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer.
    Lancet; 1986 Jan; 1(8471):48-9. PubMed ID: 2867292
    [No Abstract]   [Full Text] [Related]  

  • 14. Benefits of combination therapy with flutamide in patients relapsing after castration.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Monfette G; Emond J; Bergeron N
    Br J Urol; 1988 Apr; 61(4):341-6. PubMed ID: 3289676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re Benefits of combination therapy with flutamide in patients relapsing after castration.
    Br J Urol; 1988 Nov; 62(5):495-6. PubMed ID: 3208035
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Flamm J; Fischer M
    Wien Klin Wochenschr; 1988 Sep; 100(17):589-92. PubMed ID: 3055689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate.
    Roessler W; Hinke A; Wieland WF
    Urology; 1994 Feb; 43(2 Suppl):57-60. PubMed ID: 8116134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Suppressive effects of the antiandrogen flutamide on adrenal androgens in advanced prostate cancer patients].
    Nakazato H; Suzuki K; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):6-12. PubMed ID: 11235144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
    J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.